BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver

About this update from Biolife Solutions, Inc.

New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash. , May 29, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced the introduction of the CryoCase , an addition to its CellSeal product line. "Particulates in drug product is a growing problem that we believe can be reduced with better primary containers." Expected to be released to CGT developers in August, the CryoCase is available for demonstration at this week's ISCT event in Vancouver, Canada . Early product evaluators stated that the CryoCase's volume versatility, rigid and protective structure, and fill and retrieval port designs, allows for easy integration with their current systems generating improved throughput and streamlined procedures. The CryoCase is the first ever cryo-compatible rigid container designed for closed-system fill and retrieval for larger volumes of fluid (

View stock analysis, news, and events for Biolife Solutions, Inc.